Join Protalix Biotherapeutics for an in-person investor day in New York featuring presentations by the following key opinion leaders:

• Aleš Linhart, DSc, FESC (Charles University, Prague), who will discuss the treatment landscape for Fabry disease and perspectives on Elfabrio (pegunigalsidase alfa), a plant cell-expressed PEGylated recombinant alpha-Galactosidase-A enzyme approved for adult patients with Fabry disease.
• Naomi Schlesinger, MD (University of Utah), who will discuss the current treatment landscape for uncontrolled gout and top-line results from the First-in-Human Phase I single ascending dose clinical trial of PRX 115, a plant cell-expressed recombinant PEGylated uricase.

In addition, the event will include a corporate overview and strategy presentation by Dror Bashan, President and Chief Executive Officer of Protalix. 

A live question and answer session will follow the formal presentations.